CryoCath Reports Positive 12-Month Follow up Data from U.S. AFIB Trial

    Toronto Stock Exchange Symbol: CYT

    MONTREAL, Oct. 25 /CNW/ - CryoCath (TSX: CYT), the global leader in
cryotherapy products to treat cardiac arrhythmias, today announced positive
twelve month follow up data from the second and final cohort of 18 patients
treated during the feasibility stage (33 patients total) of its STOP AF IDE
trial. The results from the 12 month follow up confirm that 14 of the 18
subjects are free of Atrial Fibrillation (AFIB), with 12 of the 14 not taking
any anti-arrhythmic drug (AAD) therapy. The trial, now in the pivotal stage,
is assessing the Company's proprietary Arctic Front(R) catheter to treat AFIB,
the most prevalent cardiac arrhythmia affecting more than 4.3 million people
    Of the total 33 patients treated during the feasibility stage, the second
cohort of 18 patients, who have been treated with 23mm or 28mm catheters as in
the pivotal trial, has now completed the 12 month period. All patients from
the second cohort were free of detectable AFIB at six months. Three of those
patients required a second procedure which is permissible under the protocol
set for the trial.
    In the feasibility trial, the blanking period (where detectable AFIB is
not considered a treatment failure) extends 60 days after the procedure. In
the Pivotal IDE, as well as all current FDA-approved clinical trials, this
blanking period has been extended to 90 days. Under this blanking period, the
clinical success of the Arctic Front feasibility trial increased to 15 of 18
patients (83%) free from AFIB at twelve months, with 13 of those 15 patients
off AAD therapy.
    "The results from this study are very encouraging and strongly support
the effectiveness hypothesis of the STOP AF trial," said Jean-Pierre
Desmarais, Chief Scientific Officer, CryoCath. "In comparison to the
40 per cent success rate reported in medical literature using current AAD
therapies, these results are outstanding and strongly suggest that we are
creating permanent lesions, producing a significant clinical benefit."

    About Arctic Front

    Arctic Front is a minimally invasive cryo-balloon catheter designed
specifically to treat paroxysmal Atrial Fibrillation. This bi-directional,
double balloon catheter enables physicians to rapidly isolate all four
pulmonary veins for the treatment of AFIB. Approved in Europe, it has treated
more than 1200 patients in more than 27 centers.

    About CryoCath

    CryoCath - - is a medical technology company that leads
the world in cryotherapy products to treat cardiovascular disease. With a
priority focus on providing physicians with a complete solution of catheter
products to treat cardiac arrhythmias, CryoCath has multiple products approved
in the U.S., across Europe and several ROW countries. The Company is
developing additional products to expand its pipeline of products to treat
cardiac arrhythmias.
    This press release includes "forward-looking statements" that are subject
to risks and uncertainties, including with respect to the timing of regulatory
trials and their outcome. For information identifying legislative or
regulatory, economic, climatic, currency, technological, competitive and other
important factors that could cause actual results to differ materially from
those anticipated in the forward looking statements, see CryoCath's annual
report available at under the heading Risks and Uncertainties in
the Management's Discussion and Analysis section.

    %SEDAR: 00015053EF

For further information:

For further information: visit our website at, or
contact: Michael Moore, Investor Relations, Phone: (416) 815-0700 ext. 241,
Fax: (416) 815-0080, E-mail:

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890